JP2013056886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013056886A5 JP2013056886A5 JP2012221886A JP2012221886A JP2013056886A5 JP 2013056886 A5 JP2013056886 A5 JP 2013056886A5 JP 2012221886 A JP2012221886 A JP 2012221886A JP 2012221886 A JP2012221886 A JP 2012221886A JP 2013056886 A5 JP2013056886 A5 JP 2013056886A5
- Authority
- JP
- Japan
- Prior art keywords
- dioxo
- tert
- butyl
- dihydropyrimidin
- naphthalen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 79
- 238000000634 powder X-ray diffraction Methods 0.000 claims 54
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 47
- 239000003814 drug Substances 0.000 claims 45
- -1 6- (3-tert-butyl-5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -yl) -2-methoxyphenyl) naphthalen-2-yl Chemical group 0.000 claims 38
- 239000003112 inhibitor Substances 0.000 claims 36
- 229940124597 therapeutic agent Drugs 0.000 claims 35
- 241000711549 Hepacivirus C Species 0.000 claims 31
- QICWSAFHNDKQKS-UHFFFAOYSA-N sodium;methylsulfonylazanide Chemical compound [Na+].CS([NH-])(=O)=O QICWSAFHNDKQKS-UHFFFAOYSA-N 0.000 claims 26
- 125000000845 uracil-1-yl group Chemical group [*]N1C(=O)N([H])C(=O)C([H])=C1[H] 0.000 claims 24
- 239000012453 solvate Substances 0.000 claims 22
- CNUGIPSJLQIKHL-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide;sodium Chemical compound [Na].C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O CNUGIPSJLQIKHL-UHFFFAOYSA-N 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 13
- 229960000329 ribavirin Drugs 0.000 claims 13
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 102000014150 Interferons Human genes 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- RORVQFXACWAYHO-UHFFFAOYSA-N OCC[N+](C)(C)C.CS(=O)(=O)[NH-] Chemical compound OCC[N+](C)(C)C.CS(=O)(=O)[NH-] RORVQFXACWAYHO-UHFFFAOYSA-N 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 6
- 229920002477 rna polymer Polymers 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 5
- 208000005176 Hepatitis C Diseases 0.000 claims 4
- XNKPMUBPFWXXAD-UHFFFAOYSA-N O.CS(N)(=O)=O Chemical compound O.CS(N)(=O)=O XNKPMUBPFWXXAD-UHFFFAOYSA-N 0.000 claims 4
- YLJJDRHCFSYNQC-UHFFFAOYSA-N C(C)#N.CS(=O)(=O)N Chemical compound C(C)#N.CS(=O)(=O)N YLJJDRHCFSYNQC-UHFFFAOYSA-N 0.000 claims 3
- QIGVQMQJYXFLBW-UHFFFAOYSA-N C(CC)O.CS(=O)(=O)N Chemical compound C(CC)O.CS(=O)(=O)N QIGVQMQJYXFLBW-UHFFFAOYSA-N 0.000 claims 3
- OULVDSKBPHRFOK-UHFFFAOYSA-N CC(C)O.CS(=O)(=O)N Chemical compound CC(C)O.CS(=O)(=O)N OULVDSKBPHRFOK-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- JLXZKWMNOQXBCH-UHFFFAOYSA-N OCC[N+](C)(C)C.OCC[N+](C)(C)C.CS(=O)(=O)[NH-].CS(=O)(=O)[NH-] Chemical compound OCC[N+](C)(C)C.OCC[N+](C)(C)C.CS(=O)(=O)[NH-].CS(=O)(=O)[NH-] JLXZKWMNOQXBCH-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 claims 3
- 241001493065 dsRNA viruses Species 0.000 claims 3
- GIUFIPWVKLDKIG-UHFFFAOYSA-N ethanol;methanesulfonamide Chemical compound CCO.CS(N)(=O)=O GIUFIPWVKLDKIG-UHFFFAOYSA-N 0.000 claims 3
- OYGTWWUMEFMIMY-UHFFFAOYSA-N methanesulfonamide methanol Chemical compound CO.CS(=O)(=O)N OYGTWWUMEFMIMY-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- JBCZHFZUGPROKE-UHFFFAOYSA-N potassium methylsulfonylazanide Chemical compound [K+].CS(=O)(=O)[NH-] JBCZHFZUGPROKE-UHFFFAOYSA-N 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 230000029812 viral genome replication Effects 0.000 claims 3
- ZKYCMIKRCPXEPT-UHFFFAOYSA-N 2-(methanesulfonamido)ethyl acetate Chemical compound C(C)(=O)OCCNS(=O)(=O)C ZKYCMIKRCPXEPT-UHFFFAOYSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- CMRCKCWAEWYWRN-UHFFFAOYSA-N [Na+].[Na+].CS(=O)(=O)[NH-].CS(=O)(=O)[NH-] Chemical compound [Na+].[Na+].CS(=O)(=O)[NH-].CS(=O)(=O)[NH-] CMRCKCWAEWYWRN-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- NULCVGURSXLCOK-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide;2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NULCVGURSXLCOK-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 238000007614 solvation Methods 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- MGCVGJVQIPYNKV-UHFFFAOYSA-N ethyl 2-(methanesulfonamido)acetate Chemical compound CCOC(=O)CNS(C)(=O)=O MGCVGJVQIPYNKV-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- KPPQIKYWDKLYMC-UHFFFAOYSA-N methanesulfonamide;sodium Chemical compound [Na].CS(N)(=O)=O KPPQIKYWDKLYMC-UHFFFAOYSA-N 0.000 claims 1
- BEJJPPNTXTWMGM-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide;sodium Chemical compound [Na].[Na].C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O BEJJPPNTXTWMGM-UHFFFAOYSA-N 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97288107P | 2007-09-17 | 2007-09-17 | |
| US60/972,881 | 2007-09-17 | ||
| US9679208P | 2008-09-13 | 2008-09-13 | |
| US61/096,792 | 2008-09-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525103A Division JP5734655B2 (ja) | 2007-09-17 | 2008-09-17 | 抗感染症ピリミジンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013056886A JP2013056886A (ja) | 2013-03-28 |
| JP2013056886A5 true JP2013056886A5 (https=) | 2013-10-24 |
| JP5931683B2 JP5931683B2 (ja) | 2016-06-08 |
Family
ID=40308557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525103A Expired - Fee Related JP5734655B2 (ja) | 2007-09-17 | 2008-09-17 | 抗感染症ピリミジンおよびその使用 |
| JP2012221886A Expired - Fee Related JP5931683B2 (ja) | 2007-09-17 | 2012-10-04 | 抗感染症ピリミジンおよびその使用 |
| JP2015082240A Pending JP2015187106A (ja) | 2007-09-17 | 2015-04-14 | 抗感染症ピリミジンおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525103A Expired - Fee Related JP5734655B2 (ja) | 2007-09-17 | 2008-09-17 | 抗感染症ピリミジンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015082240A Pending JP2015187106A (ja) | 2007-09-17 | 2015-04-14 | 抗感染症ピリミジンおよびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8188104B2 (https=) |
| EP (3) | EP2203431B1 (https=) |
| JP (3) | JP5734655B2 (https=) |
| CN (4) | CN101842360B (https=) |
| AT (1) | ATE519746T1 (https=) |
| CA (2) | CA2699986C (https=) |
| CY (3) | CY1115514T1 (https=) |
| DK (3) | DK2639226T3 (https=) |
| ES (3) | ES2592961T3 (https=) |
| HR (2) | HRP20110809T1 (https=) |
| HU (1) | HUS1500013I1 (https=) |
| LT (1) | LTC2203431I2 (https=) |
| LU (1) | LU92666I2 (https=) |
| MX (1) | MX2010002902A (https=) |
| NL (1) | NL300729I1 (https=) |
| NO (1) | NO2015011I1 (https=) |
| PL (3) | PL2639226T3 (https=) |
| PT (3) | PT2639226T (https=) |
| RU (2) | RU2539570C2 (https=) |
| SI (2) | SI2368882T1 (https=) |
| WO (1) | WO2009039134A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2639226T3 (pl) * | 2007-09-17 | 2017-02-28 | Abbvie Bahamas Ltd. | Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania |
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| PA8796201A1 (es) | 2007-09-17 | 2009-04-23 | Abbott Lab | Agentes anti-infecciosos y su uso |
| EP2307372B1 (en) * | 2008-07-23 | 2012-04-25 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| CN102164909A (zh) | 2008-09-26 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗hcv的吡啶或吡嗪衍生物 |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| MX2011010047A (es) * | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| JP2012524752A (ja) | 2009-04-25 | 2012-10-18 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
| AR077004A1 (es) | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| MX2011012541A (es) | 2009-06-24 | 2012-08-03 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| CA2768924A1 (en) | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| CN102639504A (zh) * | 2009-11-21 | 2012-08-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| MX2012006776A (es) * | 2009-12-14 | 2012-10-05 | Merck Patent Gmbh | Inhibidores de la esfingosina quinasa. |
| CA2780526A1 (en) * | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| SG187103A1 (en) | 2010-07-16 | 2013-02-28 | Abbvie Inc | Phosphine ligands for catalytic reactions |
| CA2805748A1 (en) | 2010-07-16 | 2012-01-19 | Shashank Shekhar | Process for preparing n-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) * | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| JP6046154B2 (ja) | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ． アー． | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE202012012955U1 (de) * | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| CA2882624A1 (en) | 2012-08-21 | 2014-02-27 | Shashank Shekhar | Process for preparing antiviral compounds |
| WO2014063101A1 (en) * | 2012-10-18 | 2014-04-24 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015197028A1 (en) * | 2014-06-28 | 2015-12-30 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| CA3017751A1 (en) * | 2016-03-17 | 2017-09-21 | Fmc Corporation | Process for converting s-enantiomer to its racemic form |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| WO2017202207A1 (zh) * | 2016-05-27 | 2017-11-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的萘环化合物及药物组合物及其应用 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN117466847B (zh) * | 2022-07-22 | 2026-01-27 | 中国医药工业研究总院有限公司 | 一种利非斯特中间体苯并呋喃-6-羧酸的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| AU627906B2 (en) | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5084084A (en) | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| EP0442473B1 (en) | 1990-02-15 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| NL9001075A (https=) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| DE60034061T2 (de) | 1999-12-06 | 2007-12-13 | F. Hoffmann-La Roche Ag | 4-pyrimidinyl-n-acyl-l-phenylanine |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL167958A (en) | 2000-02-04 | 2010-11-30 | Sumitomo Chemical Co | 2-thio 3-hydroxypyridine derivatives |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| JP2005522443A (ja) * | 2002-02-14 | 2005-07-28 | フアーマセツト・リミテツド | 改変フッ素化ヌクレオシド類似体 |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| JP2007501189A (ja) * | 2003-08-01 | 2007-01-25 | ジェネラブス テクノロジーズ，インコーポレイテッド | フラビウイルス科に対する二環式イミダゾール誘導体 |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2006019831A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| AR057986A1 (es) * | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
| PA8796201A1 (es) | 2007-09-17 | 2009-04-23 | Abbott Lab | Agentes anti-infecciosos y su uso |
| PL2639226T3 (pl) | 2007-09-17 | 2017-02-28 | Abbvie Bahamas Ltd. | Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania |
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| EP2307372B1 (en) | 2008-07-23 | 2012-04-25 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
-
2008
- 2008-09-17 PL PL12182277T patent/PL2639226T3/pl unknown
- 2008-09-17 PL PL11171399T patent/PL2368882T3/pl unknown
- 2008-09-17 PT PT121822779T patent/PT2639226T/pt unknown
- 2008-09-17 ES ES12182277.9T patent/ES2592961T3/es active Active
- 2008-09-17 CN CN200880113534.8A patent/CN101842360B/zh active Active
- 2008-09-17 DK DK12182277.9T patent/DK2639226T3/en active
- 2008-09-17 ES ES08832330T patent/ES2368879T3/es active Active
- 2008-09-17 CA CA2699986A patent/CA2699986C/en not_active Expired - Fee Related
- 2008-09-17 PT PT11171399T patent/PT2368882E/pt unknown
- 2008-09-17 DK DK08832330T patent/DK2203431T3/da active
- 2008-09-17 EP EP20080832330 patent/EP2203431B1/en active Active
- 2008-09-17 RU RU2010114827/04A patent/RU2539570C2/ru active
- 2008-09-17 PL PL08832330T patent/PL2203431T3/pl unknown
- 2008-09-17 US US12/212,323 patent/US8188104B2/en active Active
- 2008-09-17 SI SI200831329T patent/SI2368882T1/sl unknown
- 2008-09-17 HR HR20110809T patent/HRP20110809T1/hr unknown
- 2008-09-17 CA CA2849420A patent/CA2849420C/en active Active
- 2008-09-17 CN CN201410659529.4A patent/CN104628655A/zh active Pending
- 2008-09-17 EP EP20110171399 patent/EP2368882B1/en not_active Not-in-force
- 2008-09-17 CN CN201210167588.0A patent/CN102746240B/zh not_active Expired - Fee Related
- 2008-09-17 MX MX2010002902A patent/MX2010002902A/es active IP Right Grant
- 2008-09-17 CN CN201410657922.XA patent/CN104628654A/zh active Pending
- 2008-09-17 SI SI200830433T patent/SI2203431T1/sl unknown
- 2008-09-17 RU RU2014147354/04A patent/RU2014147354A/ru not_active Application Discontinuation
- 2008-09-17 DK DK11171399T patent/DK2368882T3/en active
- 2008-09-17 JP JP2010525103A patent/JP5734655B2/ja not_active Expired - Fee Related
- 2008-09-17 PT PT08832330T patent/PT2203431E/pt unknown
- 2008-09-17 ES ES11171399.6T patent/ES2523864T3/es active Active
- 2008-09-17 WO PCT/US2008/076592 patent/WO2009039134A1/en not_active Ceased
- 2008-09-17 AT AT08832330T patent/ATE519746T1/de active
- 2008-09-17 EP EP12182277.9A patent/EP2639226B1/en not_active Not-in-force
-
2011
- 2011-11-03 CY CY20111101065T patent/CY1115514T1/el unknown
-
2012
- 2012-04-20 US US13/451,889 patent/US8501238B2/en active Active
- 2012-10-04 JP JP2012221886A patent/JP5931683B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/838,223 patent/US9139536B2/en active Active
-
2014
- 2014-11-12 CY CY20141100943T patent/CY1115893T1/el unknown
- 2014-11-12 HR HRP20141102 patent/HRP20141102T1/hr unknown
-
2015
- 2015-02-25 LU LU92666C patent/LU92666I2/xx unknown
- 2015-03-04 LT LTPA2015013C patent/LTC2203431I2/lt unknown
- 2015-03-17 HU HUS1500013C patent/HUS1500013I1/hu unknown
- 2015-03-26 CY CY2015013C patent/CY2015013I2/el unknown
- 2015-04-08 NL NL300729C patent/NL300729I1/nl unknown
- 2015-04-14 JP JP2015082240A patent/JP2015187106A/ja active Pending
- 2015-04-22 NO NO2015011C patent/NO2015011I1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013056886A5 (https=) | ||
| JP2011525171A5 (https=) | ||
| ES2563477T3 (es) | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina | |
| JP6553059B2 (ja) | Ｈｂｖ感染の治療のための併用療法 | |
| JP2024009953A (ja) | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| JP2005519916A5 (https=) | ||
| JP2010505902A5 (https=) | ||
| JP2010515760A5 (https=) | ||
| TW201221518A (en) | Compounds | |
| JP2010500293A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| JP2015024998A5 (https=) | ||
| JP2019511542A5 (https=) | ||
| JP2014532716A5 (https=) | ||
| JP2010504344A5 (https=) | ||
| JP2015512860A5 (https=) | ||
| JP2009535295A5 (https=) | ||
| JP2010524932A5 (https=) | ||
| IL217228A (en) | Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds | |
| TW201136945A (en) | Purine nucleoside phosphoramidate | |
| JP2012522847A5 (https=) | ||
| JP2012519691A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2017531619A5 (https=) | ||
| JP2009507896A5 (https=) |